2023-01-04 08:19:00 |
TACTI-003 trial 50% enrolment milestone has been achieved |
1 |
https://app.sharelinktechnologies.com/announcement/asx/668470b9f1cf26f3dc37cbd3954715cc |
|
2023-01-06 16:13:00 |
Notification of cessation of securities - IMM |
0 |
https://app.sharelinktechnologies.com/announcement/asx/1d99c58a3f496597e6415cea9ed46fed |
Appendix 3H (Notification of cessation of securities)
|
2023-01-30 08:34:00 |
Immutep Quarterly Activities Report and Appendix 4C |
1 |
https://app.sharelinktechnologies.com/announcement/asx/0f91b6f79db7898a58f8fb56c5e27494 |
Commitments Test Entity - Second Quarter Report
Commitments Test Entity - Second Quarter Activity Report
|
2023-02-06 08:48:00 |
Enrolment Target Reached for INSIGHT-003 Trial in NSCLC |
1 |
https://app.sharelinktechnologies.com/announcement/asx/21bd1a79cad8cf58e978457fd6c2e8a4 |
|
2023-02-24 18:57:00 |
Half Yearly Report and Accounts |
1 |
https://app.sharelinktechnologies.com/announcement/asx/abb18f77ea7d68ab05254b356fdb17af |
Half Year Directors' Statement
Half Year Directors' Report
|
2023-03-14 08:11:00 |
Initiation of Ph 2/3 Trial for Metastatic Breast Cancer |
1 |
https://app.sharelinktechnologies.com/announcement/asx/8402efcbece01468b76b0fa4005a14c5 |
|
2023-03-23 11:22:00 |
Abstract accepted for ESMO's European Lung Cancer Congress |
0 |
https://app.sharelinktechnologies.com/announcement/asx/9dc3e15abdf5451fbbb39a3b8c259f18 |
Company Administration - Other
|
2023-03-30 09:57:00 |
Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC |
1 |
https://app.sharelinktechnologies.com/announcement/asx/403c4a19d46fb25960f615878663d2bd |
|
2023-03-31 08:15:00 |
Change in substantial holding |
0 |
https://app.sharelinktechnologies.com/announcement/asx/497298999b8a2e5b45dc08f02f90e629 |
Change in substantial holding
|
2023-03-31 17:47:00 |
Positive Final Data in 2nd Line Metastatic NSCLC Patients |
1 |
https://app.sharelinktechnologies.com/announcement/asx/f988c1e15601a8fa056e52c10ade13d2 |
|
2023-04-11 08:38:00 |
Immutep Announces Changes to the Board |
0 |
https://app.sharelinktechnologies.com/announcement/asx/46097d2d86ba1badb693265c3bc04cba |
Director Appointment/Resignation
|
2023-04-11 08:42:00 |
Appendix 3X - Lis Boyce |
0 |
https://app.sharelinktechnologies.com/announcement/asx/927c8fd20ba87df1e2ac1466ee308755 |
Initial Director's Interest Notice
|
2023-04-11 09:11:00 |
Appendix 3Z - Lucy Turnbull |
0 |
https://app.sharelinktechnologies.com/announcement/asx/8318651d0edf6157326c8646f909e1b1 |
Final Director's Interest Notice
|
2023-04-11 09:59:00 |
Notification of cessation of securities - IMM |
0 |
https://app.sharelinktechnologies.com/announcement/asx/6e5b72d8925d912a07a823f4ec05d9ce |
Appendix 3H (Notification of cessation of securities)
|
2023-04-17 08:24:00 |
Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma |
1 |
https://app.sharelinktechnologies.com/announcement/asx/1169ec05c23516d2348ed7a5c455fbd9 |
|
2023-04-18 10:22:00 |
Response to ASX Aware Query |
1 |
https://app.sharelinktechnologies.com/announcement/asx/1c994fac032e56f004e27e041360aa5a |
|
2023-04-26 08:46:00 |
Immutep appoints Dr Florian Vogl as Chief Medical Officer |
0 |
https://app.sharelinktechnologies.com/announcement/asx/09b704e9bd2ace64409e2df725ede205 |
Company Administration - Other
|
2023-04-27 08:02:00 |
Immutep to announce new TACTI-002 data at ASCO 2023 |
1 |
https://app.sharelinktechnologies.com/announcement/asx/5db2283bd902adfc3d57f592caac9c98 |
|
2023-04-27 08:04:00 |
Immutep Quarterly Activities Report and Appendix 4C |
1 |
https://app.sharelinktechnologies.com/announcement/asx/48a3189ce9758eceaad39da2d354f1a2 |
Commitments Test Entity - Third Quarter Report
Commitments Test Entity - Third Quarter Activity Report
|
2023-05-01 08:12:00 |
Approval to start Efti & Bavencio trial in urothelial cancer |
1 |
https://app.sharelinktechnologies.com/announcement/asx/aeed2dc1f96c6bd870149e62922a7742 |
|
2023-05-02 08:18:00 |
Change of Director's Interest Notice - R Howard |
0 |
https://app.sharelinktechnologies.com/announcement/asx/66f4a35afb4de426f69f05f55c646c04 |
Change of Director's Interest Notice
|
2023-05-16 08:18:00 |
FDA supportive of Efti registrational trial in lung cancer |
1 |
https://app.sharelinktechnologies.com/announcement/asx/2a7448991abd55a4cd660911fe81de6e |
|
2023-05-17 09:02:00 |
Excellent initial Overall Survival Benefit in 1st line NSCLC |
1 |
https://app.sharelinktechnologies.com/announcement/asx/05407d5ff00808c133d3cbd464ba6230 |
|
2023-05-24 09:01:00 |
Promising New Data in 1st line NSCLC from INSIGHT-003 Trial |
1 |
https://app.sharelinktechnologies.com/announcement/asx/14e57c817bf8a3138d1bfb8defe72c67 |
|
2023-05-25 08:19:00 |
1st patient dosed in AIPAC-003 ph2/3 breast cancer trial |
1 |
https://app.sharelinktechnologies.com/announcement/asx/e33ba23f3e92b84bb780e4e25a99ff02 |
|
2023-05-26 08:24:00 |
Publication of Abstracts for ASCO 2023 Annual Meeting |
1 |
https://app.sharelinktechnologies.com/announcement/asx/f0d78fd5e831c528ed67cc7d1cbe2827 |
|
2023-05-29 08:20:00 |
Charles River Laboratories to run IMP761 Toxicology Study |
1 |
https://app.sharelinktechnologies.com/announcement/asx/7f1929f37eb0b32c87e76e3ef0bdbe70 |
|
2023-05-31 09:21:00 |
Trading Halt |
1 |
https://app.sharelinktechnologies.com/announcement/asx/055d8400a23745a1a5c5cebf379c5a6c |
|
2023-05-31 09:38:00 |
A$80 million fully underwritten equity raising |
1 |
https://app.sharelinktechnologies.com/announcement/asx/1621e575fb452cff0a043f8abadd02fa |
|
2023-05-31 10:10:00 |
Immutep Capital Raising Presentation |
1 |
https://app.sharelinktechnologies.com/announcement/asx/ed51d503bf41f37d1b9b19cbb0c8fa69 |
|
2023-05-31 10:25:00 |
Proposed issue of securities - IMM |
0 |
https://app.sharelinktechnologies.com/announcement/asx/ee1c887f98c0a336a65d4c7e8bd2328b |
|
2023-05-31 10:47:00 |
Cleansing Notice |
0 |
https://app.sharelinktechnologies.com/announcement/asx/68fa8c1531978aa5eb7069321439442a |
|
2023-06-01 08:22:00 |
Change in substantial holding |
0 |
https://app.sharelinktechnologies.com/announcement/asx/d6a58fc9a9ee5103744f112d7dd1fa3e |
Change in substantial holding
|
2023-06-02 09:02:00 |
Immutep completes institutional pro-rata offer & placement |
1 |
https://app.sharelinktechnologies.com/announcement/asx/0073c0db2a6071e0e66713a3603f7b0d |
|
2023-06-05 08:41:00 |
Positive final data in 2nd line head and neck cancer at ASCO |
0 |
https://app.sharelinktechnologies.com/announcement/asx/39832be51ce0be052165bb18a77fa66a |
|
2023-06-06 08:13:00 |
Immutep retail entitlement offer booklet |
0 |
https://app.sharelinktechnologies.com/announcement/asx/5d26c1365f2a14e7ea7923ef9e5e16f4 |
|
2023-06-06 08:36:00 |
Immutep letter to ineligible shareholders |
0 |
https://app.sharelinktechnologies.com/announcement/asx/100bb699dfa1f790212e060739275820 |
|
2023-06-08 10:20:00 |
Application for quotation of securities - IMM |
0 |
https://app.sharelinktechnologies.com/announcement/asx/aff1507139a9344a00bfabde4c6e564e |
Appendix 2A (Application for Quotation of Securities
|
2023-06-08 10:51:00 |
Cleansing Notice |
0 |
https://app.sharelinktechnologies.com/announcement/asx/9339ba3880470d7aa64531d15aba5a28 |
|